Alembic Pharmaceuticals Limited announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for testosterone topical solution USP, 30 mg per pump actuation.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Axiron topical solution, 30 mg per pump actuation, of Eli Lilly and Company (Lilly).Testosterone topical solution USP, 30 mg per pump actuation is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).Testosterone topical solution USP, 30 mg per pump actuation has an estimated market size of US$ 21 million for twelve months ending March 2021 according to IQVIA.Alembic has a cumulative total of 145 ANDA approvals (127 final approvals and 18 tentative approvals) from US FDA.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!